(Q33214444)

English

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

2

object named as

Cunningham D

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

author name string

Rao S

1

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Hawkins RE

3

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Hill ME

4

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Smith D

5

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Daniel F

6

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Ross PJ

7

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Oates J

8

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Norman AR

9

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1650-1654

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

21 June 2018

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602576

21 January 2018

Cholangiocarcinoma: the "other" liver cancer on the rise

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856037

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856037

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/15856037

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602576

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33214444&oldid=2195145912"